NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today announced it raised $105 million in private funding, which will allow it to expand its immunosequencing research platform and clinical diagnostic products.

Viking Global Investors contributed $5 million to complete Adaptive Bio's Series C financing round and $100 million into its Series D round. Viking was the sole investor in the Series D financing and will take an observer seat on Adaptive Bio's board, Seattle-based Adaptive Bio said.

It has raised a total of $120 million, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.